MALVERN, Pa. - Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company, announced today the completion of data cleaning for its phase II/III study of buntanetap in patients with mild to moderate Alzheimer's disease. The company expects to release topline efficacy data in April.
The phase II/III study was a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy, safety, and tolerability of buntanetap. The study involved a dose-ranging approach in which patients received one of three doses of the drug or a placebo alongside their standard care for 12 weeks. Out of over 700 patients screened, 353 were enrolled, and 327 completed the study.
"We are excited to share that we now move from data cleaning to organization and statistical evaluation of data for our Alzheimer's study, which was completed in February," said Cheng Fang, Ph.D., Senior Vice President of Annovis. "To clean data this fast is truly a tremendous achievement."
Buntanetap, formerly known as Posiphen or ANVS401, aims to combat neurodegeneration by inhibiting the formation of various neurotoxic proteins, potentially reversing neurodegeneration in Alzheimer's disease.
"We are grateful to the participants who enrolled and completed the study as well as their caregivers and families for supporting their loved one's involvement in this trial," expressed Melissa Gaines, Senior Vice President, Clinical Operations.
Annovis Bio is focused on addressing neurodegeneration, such as Alzheimer's Disease and Parkinson's Disease, with the intention of restoring axonal and synaptic activity to treat memory loss and dementia associated with these conditions.
This news article is based on a press release statement from Annovis Bio, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.